根据分子分型优化乳腺癌局部及全身治疗策略十分必要。对于luminal型患者手术治疗可提前,内分泌治疗是基础。对于HER-2过表达型患者,术前明确 HER-2状态并辅以靶向药物的治疗是关键。对于三阴性乳腺癌患者,早期诊断和首次治疗很重要,尤其是术前充分的化疗,而局部手术处理无需过度。
综上所述,基于乳腺癌分子分型进行分类治疗是当前乳腺癌治疗的基本原则,但是更加精确的分类治疗仍需要大型临床试验的研究证实。随着精准医学研究的不断开展,新的分子标志物不断发现,乳腺癌分子分型会更加精细、准确,乳腺癌个体化治疗也会更加精准。
参考文献
【1】Collignon J, Lousberg L, Schroeder H et al. Triple-negative breast cancer: treatment challenges and solutions.Breast Cancer (Dove Med Press). 2016 May 20;8:93-107. doi: 10.2147/BCTT.S69488. eCollection 2016.
【2】Blichert-Toft M, Nielsen M, Düring M et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol.Acta Oncol. 2008;47(4):672-81. doi: 10.1080/02841860801971439.
【3】Gangi A, Mirocha J, Leong T, Giuliano AE.Triple-negative breast cancer is not associated with increased likelihood of nodal metastases.Ann Surg Oncol. 2014 Dec;21(13):4098-103. doi: 10.1245/s10434-014-3989-7. Epub 2014 Aug 26.
【4】Liedtke C, Thill M, Hanf V et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and MetastaticBreast Cancer: Update 2015. AGO Breast Committee.Breast Care (Basel). 2015 Jul;10(3):199-205. doi: 10.1159/000431248. Epub 2015 Jun 18. No abstract available.
【5】Hu XC, Zhang J, Xu BH et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negativebreast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol. 2015 Apr;16(4):436-46. doi: 10.1016/S1470-2045(15)70064-1. Epub 2015 Mar 18.